2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 146

Major Cardiovascular Events Among an Inception Cohort of Seniors with Rheumatoid Arthritis
Abstract Number: 1499

Major Salivary Gland Ultrasonography Bed-Side and Still Image Scoring – a Pilot Comparison in Juvenile Sjögren’s Syndrome
Abstract Number: 1879

Majority of Rheumatoid Arthritis Patients in Clinical Remission As Defined By DAS-28, CDAI, SDAI and RAPID-3 Have No Signal on Ultrasound Power Doppler
Abstract Number: 1283

Male Patients Have a More Severe Course As Female Patients with Diffuse Juvenile Systemic Scleroderma? Results from the Juvenile Scleroderma Inception Cohort Www.Juvenile-Scleroderma.Com
Abstract Number: 1116

Management of Acute Gout in Hospitalized Patients and Risk Factors for Xanthine Oxidase Inhibitor (XOI) Discontinuation or Dose Reduction
Abstract Number: 1139

Management of Gout – a Survey for Healthcare Providers in South Australia
Abstract Number: 406

Mapping Changes in Monocyte and Macrophage Populations in the Synovium: An Aging Study in Arthritic KRN Ag7 Mice
Abstract Number: 2238

Mapping Paindetect, a Neuropathic Pain Screening Tool, to Patient-Reported Outcomes Measurement Information System (PROMIS) 29 in Patients with Rheumatoid Arthritis: Developing a Neuropathic Pain Scale As a Measure of Treatment Outcome
Abstract Number: 1124

Marked Variability of Circulating Urate Concentrations in Banked Samples Based on Sample Type and Assay
Abstract Number: 789

Markers of Inflammation and Patient-Reported Measures As Predictors of Relapse in Giant Cell Arteritis
Abstract Number: 2420

Mass Cytometry Analysis of CD4+ T Cells in Patients with Rheumatoid Arthritis
Abstract Number: 179

Mass Spectrometry Imaging of Synovium: A Novel Approach to Classify the Rheumatoid and Psoriatic Arthritis Patients
Abstract Number: 2115

Mast Cell Activation Features in Ehlers-Danlos/Joint Hypermobility Patients: A Retrospective Analysis in Light of an Emerging Disease Cluster
Abstract Number: 788

Mast Cell Mediated Inhibition of Systemic IL-6 in candida Albicans Water-Soluble Fraction (CAWS) Induced Model of Large Vessel Vasculitis
Abstract Number: 552

Mast Cells Are Involved in the Pathogenesis of Sjögren Syndrome By Inducing Tissue Fibrosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].